News from Friday, February 27, 2026
Articles
Risankizumab Effective in Crohn's, Real-World Data Show
(2/27, Medscape) reports “...Among patients with Crohn's disease, risankizumab yielded significant improvements in clinical and endoscopic outcomes and had a favourable safety profile; prior ustekinumab exposure was associated with lower clinical remission at week 12.” Full
IRA Price-Setting Is 'Not a Negotiation'
(2/26, The Washington Post) reports “...On a recent WP Intelligence Live Briefing, ‘Washington's new push on drug pricing,’ PhRMA Executive Vice President Elizabeth Carpenter outlined the pharmaceutical industry's concerns with the Inflation Reduction Act - including why manufacturers argue the current framework functions more as price-setting than negotiation.” Subscription Required
Press Releases
OneMedNet Announces Next Phase of Commercial Launch with its Real-World Data (RWD) Platform powered by Palantir Foundry
(2/27, OnedMedNet Press Release) “...‘OneMedNet’s platform is redefining how organizations access and operationalize real-world data through the continued expansion of our products and solutions,’ said Aaron Green, CEO & President. ‘Customer feedback has reinforced the platform’s performance, speed, and depth of discovery. We believe this traction validates our strategy of combining conversational AI-driven search with scalable, prospective data feeds, strengthening customer confidence as we expand subscriptions and deliver fast, intuitive value for Real-World evidence generation.’” Full
Journals
Comparative Effectiveness and Safety of Denosumab Versus Bisphosphonates in Elderly Patients with Cancer Bone Metastases: A Target Trial Emulation Study
Che-Wei Liu, et al.
February 17, 2026, Life
Multicenter Real-World Outcomes of Risankizumab in Crohn’s Disease: The RESOLVE IG-IBD Study
Scaldaferri, Franco, et al.
February 18, 2026, The American Journal of Gastroenterology
The American Journal of Gastroenterology
Comparing the Efficacy of Cipaglucosidase Alfa plus Miglustat with Alglucosidase Alfa for Late-Onset Pompe Disease: An Expanded Network Meta-Analysis Utilizing Patient-Level and Aggregate Data
Shuai Fu, et al.
February 27, 2026, Journal of Comparative Effectiveness Research
Journal of Comparative Effectiveness Research
Advancing Real-World Evidence Harmonization: Lessons from the UK, EMA and Global Policy Frameworks
Alexandros Sagkriotis
February 27, 2026, Journal of Comparative Effectiveness Research
Comparative Effectiveness of Dolutegravir + Lamivudine Versus Three-Drug Regimens in Swedish Clinical Practice: A Nationwide Study
Erik Sörstedt, et al.
March 2026, Journal of the International AIDS Society